Pertento Partners LLP Has $41.23 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Pertento Partners LLP grew its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 22.8% in the 4th quarter, Holdings Channel.com reports. The fund owned 3,484,918 shares of the company’s stock after purchasing an additional 646,865 shares during the quarter. Roivant Sciences makes up 3.5% of Pertento Partners LLP’s holdings, making the stock its 13th largest holding. Pertento Partners LLP’s holdings in Roivant Sciences were worth $41,227,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of ROIV. GAMMA Investing LLC raised its stake in shares of Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. increased its position in Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after buying an additional 1,507 shares during the last quarter. Quarry LP raised its stake in Roivant Sciences by 50.0% in the third quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after buying an additional 2,500 shares during the period. Blue Trust Inc. lifted its position in shares of Roivant Sciences by 550.1% in the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock valued at $91,000 after buying an additional 6,667 shares during the last quarter. Finally, HighTower Advisors LLC bought a new position in shares of Roivant Sciences during the 4th quarter worth approximately $121,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $17.10.

Roivant Sciences Stock Down 1.0 %

Shares of Roivant Sciences stock opened at $10.38 on Friday. The company has a 50-day simple moving average of $10.74 and a two-hundred day simple moving average of $11.41. Roivant Sciences Ltd. has a twelve month low of $9.96 and a twelve month high of $13.06. The stock has a market capitalization of $7.41 billion, a price-to-earnings ratio of -69.20 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, sell-side analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Roivant Sciences news, CAO Rakhi Kumar sold 227,500 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the sale, the chief accounting officer now directly owns 163,264 shares in the company, valued at $1,702,843.52. This represents a 58.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Eric Venker sold 177,704 shares of Roivant Sciences stock in a transaction on Monday, December 30th. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16. Following the completion of the transaction, the chief operating officer now owns 740,976 shares in the company, valued at approximately $8,550,863.04. The trade was a 19.34 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,573,245 shares of company stock worth $17,079,242. Company insiders own 7.90% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.